Kala Pharmaceuticals, now known as KALA BIO, is a clinical-stage biopharmaceutical company that focuses on researching, developing, and commercializing innovative therapies for rare eye diseases. With a strong dedication to improving patients' lives, Kala has developed and launched two commercial products. The first is EYSUVIS®, which is the only prescription therapy specifically designed for the short-term management of dry eye disease's signs and symptoms.

The second is INVELTYS®, a twice-a-day corticosteroid that effectively treats post-operative ocular inflammation and pain following ocular surgery. In July 2022, Kala successfully completed the sale of its commercial products to Alcon Inc. As part of its growth strategy, Kala acquired Combangio, Inc.

This asset is a mesenchymal stem cell secretome (MSC-S), and Kala is focused on developing biologic therapies utilizing this proprietary platform. Kala's development pipeline includes KPI-012, which is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease that impairs corneal healing. Additionally, Kala is evaluating KPI-012 for potential expansion into other indications for rare front-of-the-eye diseases.

With a commitment to advancing eye health, Kala Pharmaceuticals strives to make a difference in the lives of patients with rare eye diseases